203 related articles for article (PubMed ID: 3019519)
1. Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma.
Tan RS; Li JS; Grill SP; Nutter LM; Cheng YC
Cancer Res; 1986 Oct; 46(10):5024-8. PubMed ID: 3019519
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome.
Jones JF; Williams M; Schooley RT; Robinson C; Glaser R
Arch Intern Med; 1988 Sep; 148(9):1957-60. PubMed ID: 2843138
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
6. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
[TBL] [Abstract][Full Text] [Related]
7. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
9. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
10. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
11. EBV-specific humoral antibodies in nasopharyngeal carcinoma patients in Cuba.
Ruiz R; Gurtsevich V; Le Riverend E
Neoplasma; 1979; 26(2):125-31. PubMed ID: 224330
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
14. Circulating immune complexes in patients with nasopharyngeal carcinoma.
Wolf GT; Wolfe RA
Laryngoscope; 1990 Mar; 100(3):302-8. PubMed ID: 1689798
[TBL] [Abstract][Full Text] [Related]
15. [Screening of dominant epitopes of antigens related to antibodies in the sera of patients with nasopharyngeal carcinoma].
Zhang Y; Xiao XB; Zhang CQ; Li JL; Sun Y; Ye YZ; Feng KT
Ai Zheng; 2004 Sep; 23(9):999-1004. PubMed ID: 15363190
[TBL] [Abstract][Full Text] [Related]
16. Induction of virus enzymes by phorbol esters and n-butyrate in Epstein-Barr virus genome-carrying Raji cells.
Nutter LM; Grill SP; Li JS; Tan RS; Cheng YC
Cancer Res; 1987 Aug; 47(16):4407-12. PubMed ID: 3038311
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of Epstein-Barr virus derived from a nasopharyngeal carcinoma that has transforming and lytic properties.
Sato H; Takimoto T; Ogura H; Tanaka J; Hatano M; Glaser R
J Natl Cancer Inst; 1986 Jun; 76(6):1019-24. PubMed ID: 3012175
[TBL] [Abstract][Full Text] [Related]
18. Expression of the DNase encoded by the BGLF5 gene of Epstein-Barr virus in nasopharyngeal carcinoma epithelial cells.
Sbih-Lammali F; Berger F; Busson P; Ooka T
Virology; 1996 Aug; 222(1):64-74. PubMed ID: 8806488
[TBL] [Abstract][Full Text] [Related]
19. Anti-EBV antibody titers in Italian patients with nasopharyngeal carcinoma.
Pirodda E; Caliceti U; Testoni S
J Exp Pathol; 1987; 3(4):479-83. PubMed ID: 2842481
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
